Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marie Ralff, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lulla AR, Zhou Y, Ralff MD, Lev A, Dicker DT, El-Deiry WS. miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells. Am J Cancer Res. 2022; 12(1):315-326. PMID: 35141020; PMCID: PMC8822281.
  2. Jhaveri AV, Zhou L, Ralff MD, Lee YS, Navaraj A, Carneiro BA, Safran H, Prabhu VV, Ross EA, Lee S, El-Deiry WS. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo. Cancer Biol Ther. 2021 12 02; 22(10-12):607-618. PMID: 34856854; PMCID: PMC8726623.
    Citations:    Fields:    Translation:HumansAnimalsCells
  3. Ray JE, Ralff MD, Jhaveri A, Zhou L, Dicker DT, Ross EA, El-Deiry WS. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo. Cancer Biol Ther. 2021 12 02; 22(10-12):554-563. PMID: 34696710; PMCID: PMC8726732.
    Citations:    Fields:    Translation:HumansAnimalsCells
  4. Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, Carneiro B, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L, Stogniew M, Allen JE, Oster W, El-Deiry WS. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. Neoplasia. 2020 12; 22(12):725-744. PMID: 33142238.
    Citations: 28     Fields:    Translation:HumansAnimalsCells
  5. Ralff MD, Jhaveri A, Ray JE, Zhou L, Lev A, Campbell KS, Dicker DT, Ross EA, El-Deiry WS. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. Oncotarget. 2020 Oct 20; 11(42):3753-3769. PMID: 33144917.
    Citations: 5     Fields:    
  6. Ralff MD, El-Deiry WS. TRAIL pathway targeting therapeutics. Expert Rev Precis Med Drug Dev. 2018; 3(3):197-204. PMID: 30740527; PMCID: PMC6366666.
    Citations: 9     
  7. Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest. 2018 06 01; 128(6):2325-2338. PMID: 29533922; PMCID: PMC5983321.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  8. Lev A, Lulla AR, Ross BC, Ralff MD, Makhov PB, Dicker DT, El-Deiry WS. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. Mol Cancer Res. 2018 05; 16(5):754-766. PMID: 29588330; PMCID: PMC5932216.
    Citations: 12     Fields:    Translation:HumansCells
  9. Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS. Role of Dopamine Receptors in the Anticancer Activity of ONC201. Neoplasia. 2018 01; 20(1):80-91. PMID: 29216597; PMCID: PMC5725157.
    Citations: 46     Fields:    Translation:HumansCells
  10. Ralff MD, Lulla AR, Wagner J, El-Deiry WS. ONC201: a new treatment option being tested clinically for recurrent glioblastoma. Transl Cancer Res. 2017 Oct; 6(Suppl 7):S1239-S1243. PMID: 30175049; PMCID: PMC6117120.
    Citations: 11     
  11. Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 2017 Oct 10; 8(47):81776-81793. PMID: 29137221.
    Citations: 21     Fields:    
  12. Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One. 2017; 12(8):e0180541. PMID: 28767654.
    Citations: 14     Fields:    Translation:HumansCells
  13. Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 02; 16(19):1790-1799. PMID: 28489985; PMCID: PMC5628644.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  14. Ralff MD, Kline CLB, Küçükkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. Mol Cancer Ther. 2017 07; 16(7):1290-1298. PMID: 28424227; PMCID: PMC5564301.
    Citations: 22     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Ralff's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (62)
Co-Authors (2)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.